within Pharmacolibrary.Drugs.ATC.N;

model N07XX12
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 5.016666666666666e-05,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07XX12</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Patisiran is an RNA interference (RNAi) therapeutic agent approved for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It works by silencing the transthyretin (TTR) gene, thereby reducing the production of mutant and wild-type TTR protein which forms amyloid deposits.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with hereditary transthyretin-mediated amyloidosis; values pertain to patisiran lipid nanoparticle (LNP) formulation after intravenous administration.</p><h4>References</h4><ol><li><p>Badri, P, et al., &amp; Robbie, GJ (2023). Pharmacokinetics and Pharmacodynamics of Patisiran in Patients with hATTR Amyloidosis and with Polyneuropathy After Liver Transplantation. <i>Clinical pharmacokinetics</i> 62(10) 1509–1522. DOI:<a href=\"https://doi.org/10.1007/s40262-023-01292-w\">10.1007/s40262-023-01292-w</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37639169/\">https://pubmed.ncbi.nlm.nih.gov/37639169</a></p></li><li><p>Zhang, X, et al., &amp; Robbie, GJ (2020). Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure-Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin-Mediated (hATTR) Amyloidosis. <i>Journal of clinical pharmacology</i> 60(1) 37–49. DOI:<a href=\"https://doi.org/10.1002/jcph.1480\">10.1002/jcph.1480</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31322739/\">https://pubmed.ncbi.nlm.nih.gov/31322739</a></p></li><li><p>Zhang, X, et al., &amp; Robbie, GJ (2020). Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis. <i>Journal of clinical pharmacology</i> 60(5) 573–585. DOI:<a href=\"https://doi.org/10.1002/jcph.1553\">10.1002/jcph.1553</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31777097/\">https://pubmed.ncbi.nlm.nih.gov/31777097</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07XX12;
